The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

KU Hematology & Medical Oncology Review 2019
A

KU ASCO 2019 CML Updates - Criteria for Treatment Discontinuation & Treatment-Free Remission After Nilotinib (ENESTop Study)

By KU Hematology & Medical Oncology Review 2019 FEATURING Abdulraheem Yacoub
By KU Hematology & Medical Oncology Review 2019 FEATURING Abdulraheem Yacoub
0 views
August 2, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse
Hematologic Malignancies
09:31
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Hairy Cell Leukemia Highlights - Moxetumomab Pasudotox …

Feat. A. Yacoub
07:15
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 CML Updates - Criteria for Treatment Discontinuation &a…

Feat. A. Yacoub
09:20
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 MDS & MPN Update - Luspatercept in Lower-Risk MDS &…

Feat. A. Yacoub
15:41
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Targeted Therapy Drugs for AML - CPX-351, FLT3, IDH Inh…

Feat. T. Lin
12:21
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Update on Recent Developments in AML - CX-01, HuF59 Ant…

Feat. T. Lin
10:39
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Myeloma Update: Lenalidomide vs Observation in Patients…

Feat. A. Abdallah
06:58
KU Hematology & Medical Oncology Review 2019

KU ASCO Review 2019: FDA Approval of Daratumumab in Combination with…

Feat. A. Abdallah
05:36
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Myeloma Update: Efficacy of KRd With or Without Transpl…

Feat. A. Abdallah
06:42
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Myeloma Update: Does Subcutaneous Daratumumab Decrease …

Feat. A. Abdallah
04:31
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019: Update on CLL Preferred Therapy - BR vs Ibrutinib &…

Feat. M. Hoffmann
08:34
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019: Update on CLL Preferred Therapy - Venetoclax + Obinutu…

Feat. M. Hoffmann
12:53
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Non Hodgkin Lymphoma Update : Polatuzumab Vedotin for R…

Feat. M. Hoffmann